625 related articles for article (PubMed ID: 28289035)
1. WCK 5107 (Zidebactam) and WCK 5153 Are Novel Inhibitors of PBP2 Showing Potent "β-Lactam Enhancer" Activity against Pseudomonas aeruginosa, Including Multidrug-Resistant Metallo-β-Lactamase-Producing High-Risk Clones.
Moya B; Barcelo IM; Bhagwat S; Patel M; Bou G; Papp-Wallace KM; Bonomo RA; Oliver A
Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28289035
[TBL] [Abstract][Full Text] [Related]
2. Potent β-Lactam Enhancer Activity of Zidebactam and WCK 5153 against Acinetobacter baumannii, Including Carbapenemase-Producing Clinical Isolates.
Moya B; Barcelo IM; Bhagwat S; Patel M; Bou G; Papp-Wallace KM; Bonomo RA; Oliver A
Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28848013
[TBL] [Abstract][Full Text] [Related]
3.
Moya B; Barcelo IM; Cabot G; Torrens G; Palwe S; Joshi P; Umarkar K; Takalkar S; Periasamy H; Bhagwat S; Patel M; Bou G; Oliver A
Antimicrob Agents Chemother; 2019 May; 63(5):. PubMed ID: 30782985
[TBL] [Abstract][Full Text] [Related]
4. Structural Characterization of Diazabicyclooctane β-Lactam "Enhancers" in Complex with Penicillin-Binding Proteins PBP2 and PBP3 of Pseudomonas aeruginosa.
Rajavel M; Kumar V; Nguyen H; Wyatt J; Marshall SH; Papp-Wallace KM; Deshpande P; Bhavsar S; Yeole R; Bhagwat S; Patel M; Bonomo RA; van den Akker F
mBio; 2021 Feb; 12(1):. PubMed ID: 33593978
[TBL] [Abstract][Full Text] [Related]
5. WCK 5222 (cefepime/zidebactam) antimicrobial activity tested against Gram-negative organisms producing clinically relevant β-lactamases.
Sader HS; Rhomberg PR; Flamm RK; Jones RN; Castanheira M
J Antimicrob Chemother; 2017 Jun; 72(6):1696-1703. PubMed ID: 28333332
[TBL] [Abstract][Full Text] [Related]
6. Molecular Characterization of WCK 5222 (Cefepime/Zidebactam)-Resistant Mutants Developed from a Carbapenem-Resistant Pseudomonas aeruginosa Clinical Isolate.
Pan X; Zhao X; Song Y; Ren H; Tian Z; Liang Q; Jin Y; Bai F; Cheng Z; Feng J; Wu W
Microbiol Spectr; 2022 Feb; 10(1):e0267821. PubMed ID: 35196805
[TBL] [Abstract][Full Text] [Related]
7. In vitro activity of cefepime/zidebactam (WCK 5222) against Gram-negative bacteria.
Livermore DM; Mushtaq S; Warner M; Vickers A; Woodford N
J Antimicrob Chemother; 2017 May; 72(5):1373-1385. PubMed ID: 28158732
[TBL] [Abstract][Full Text] [Related]
8. Effective inhibition of PBPs by cefepime and zidebactam in the presence of VIM-1 drives potent bactericidal activity against MBL-expressing Pseudomonas aeruginosa.
Moya B; Bhagwat S; Cabot G; Bou G; Patel M; Oliver A
J Antimicrob Chemother; 2020 Jun; 75(6):1474-1478. PubMed ID: 32083659
[TBL] [Abstract][Full Text] [Related]
9. WCK 5222 (Cefepime-Zidebactam) Antimicrobial Activity against Clinical Isolates of Gram-Negative Bacteria Collected Worldwide in 2015.
Sader HS; Castanheira M; Huband M; Jones RN; Flamm RK
Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28242660
[TBL] [Abstract][Full Text] [Related]
10.
Karlowsky JA; Hackel MA; Bouchillon SK; Sahm DF
Antimicrob Agents Chemother; 2020 Nov; 64(12):. PubMed ID: 32928739
[TBL] [Abstract][Full Text] [Related]
11. Strategic Approaches to Overcome Resistance against Gram-Negative Pathogens Using β-Lactamase Inhibitors and β-Lactam Enhancers: Activity of Three Novel Diazabicyclooctanes WCK 5153, Zidebactam (WCK 5107), and WCK 4234.
Papp-Wallace KM; Nguyen NQ; Jacobs MR; Bethel CR; Barnes MD; Kumar V; Bajaksouzian S; Rudin SD; Rather PN; Bhavsar S; Ravikumar T; Deshpande PK; Patil V; Yeole R; Bhagwat SS; Patel MV; van den Akker F; Bonomo RA
J Med Chem; 2018 May; 61(9):4067-4086. PubMed ID: 29627985
[TBL] [Abstract][Full Text] [Related]
12. The Novel β-Lactam Enhancer Zidebactam Augments the
Bhagwat SS; Periasamy H; Takalkar SS; Palwe SR; Khande HN; Patel MV
Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30670419
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of human-simulated bronchopulmonary exposures of cefepime, zidebactam and the combination (WCK 5222) against MDR Pseudomonas aeruginosa in a neutropenic murine pneumonia model.
Kidd JM; Abdelraouf K; Nicolau DP
J Antimicrob Chemother; 2020 Jan; 75(1):149-155. PubMed ID: 31641765
[TBL] [Abstract][Full Text] [Related]
14. WCK 4234, a novel diazabicyclooctane potentiating carbapenems against Enterobacteriaceae, Pseudomonas and Acinetobacter with class A, C and D β-lactamases.
Mushtaq S; Vickers A; Woodford N; Livermore DM
J Antimicrob Chemother; 2017 Jun; 72(6):1688-1695. PubMed ID: 28333319
[TBL] [Abstract][Full Text] [Related]
15. Activity of cefepime/zidebactam (WCK 5222) against Enterobacteriaceae, Pseudomonas aeruginosa and Acinetobacter baumannii endemic to New York City medical centres.
Khan Z; Iregui A; Landman D; Quale J
J Antimicrob Chemother; 2019 Oct; 74(10):2938-2942. PubMed ID: 31298277
[TBL] [Abstract][Full Text] [Related]
16. Inoculum effects of cefepime/zidebactam (WCK 5222) and ertapenem/zidebactam (WCK 6777) for Enterobacterales in relation to β-lactamase type and enhancer effect, as tested by BSAC agar dilution.
Mushtaq S; Vickers A; Chaudhry A; Woodford N; Livermore DM
J Antimicrob Chemother; 2022 Jun; 77(7):1916-1922. PubMed ID: 35368056
[TBL] [Abstract][Full Text] [Related]
17. Activity of cefepime/zidebactam (WCK 5222) against 'problem' antibiotic-resistant Gram-negative bacteria sent to a national reference laboratory.
Mushtaq S; Garello P; Vickers A; Woodford N; Livermore DM
J Antimicrob Chemother; 2021 May; 76(6):1511-1522. PubMed ID: 33760082
[TBL] [Abstract][Full Text] [Related]
18. In vitro activity of cefepime/zidebactam (WCK 5222) against recent Gram-negative isolates collected from high resistance settings of Greek hospitals.
Bhagwat SS; Legakis NJ; Skalidis T; Loannidis A; Goumenopoulos C; Joshi PR; Shrivastava R; Palwe SR; Periasamy H; Patel MV; Chatzipanagiotou S;
Diagn Microbiol Infect Dis; 2021 Jul; 100(3):115327. PubMed ID: 33744624
[TBL] [Abstract][Full Text] [Related]
19. Comparative Evaluation of the
Mullane EM; Avery LM; Nicolau DP
Antimicrob Agents Chemother; 2020 Feb; 64(3):. PubMed ID: 31844009
[TBL] [Abstract][Full Text] [Related]
20. Antimicrobial activity of cefepime/zidebactam (WCK 5222), a β-lactam/β-lactam enhancer combination, against clinical isolates of Gram-negative bacteria collected worldwide (2018-19).
Sader HS; Mendes RE; Duncan LR; Carvalhaes CG; Castanheria M
J Antimicrob Chemother; 2022 Sep; 77(10):2642-2649. PubMed ID: 35897129
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
